Globally, cardiovascular diseases constitute the leading cause of death and hospitalization in Western countries in general and in Spain in particular. The Program of Cardiovascular Diseases focuses on the study of chronic heart failure, atrial fibrillation and vascular pathologies related to ischemic cerebral events and peripheral artery disease.
The Program research focuses on:
-Understanding the mechanisms through which the ventricular myocardium, atrial endocardium and arterial wall are damaged in processes involving heart failure, atrial fibrillation and stroke.
-Developing non-invasive blood biomarkers for the early detection of the lesions caused by these mechanisms, with diagnostic and preventive usefulness in these processes.
-Identifying novel relevant therapeutic targets related to the pathophysiological mechanisms involved in these pathologies and designing new drugs for more their effective treatment.
The research team is multidisciplinary, composed of specialists in both clinical and basic research with different expertise. Our projects follow a marked translational approach, being implemented in close collaboration with the Departments of Cardiology and Cardiac Surgery, Hematology, Nephrology, Internal Medicine, and Radiology from the Clínica Universidad de Navarra, as well as CIMA's own Translational Development Program. Additionally, we have also developed experimental models covering a full range of needs (including in vitro models, in silico models for chemical modeling and in vivo animal models).
The Program is part of the “Cardiovascular and Renal Diseases Area” of the Health Research Institute of Navarra (IdiSNA) and it also belongs to the Spanish Network for Biomedical Research Centres in Cardiovascular Diseases (CIBERCV) financed by the Instituto de Salud Carlos III. It also participates in several multinational research consortia within the European Commission FP7 and H2020 initiatives. Finally, it is also involved on joint research projects with academic centers and biotech and pharmaceutical companies in Spain, other European countries and the United States.